English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background. Promoter hypermethylation of the SMAD4 gene has been registered   in some cancer types, but in general doesn?t appear to be a frequent event in   carcinogenesis. However, only a few published studies deal with this topic   and not many cancer types have been analyzed. The aim of this study was to   establish SMAD4 gene promoter methylation status in pancreatic and   endometrial cancers. Methods. Patients included in the study (62 subjects)   were diagnosed and surgically treated at the University of Belgrade, Clinical   Center of Serbia. Patients with pancreatic carcinoma (17 subjects) underwent   surgical removal of the pancreatic adenocarcinoma at the First Surgical   Clinic, while the patients with endometrial carcinoma (45 subjects) underwent   hysterectomy with adnexectomy at the Institute for Gynecology and Obstetrics.   Extraction of DNA from fresh tissue samples was performed and the methylation   status of the SMAD4 gene promoter was studied by a previously designed   PCR-based HpaII and MspI restriction enzyme assay. The resulting PCR products   were analyzed by electrophoresis in 2% agarose gels. Results. Neither of the   analyzed samples was found to be hypermethylated. Conclusion. This is the   first report on SMAD4 methylation status in pancreatic and endometrial tumor   specimens, and supports the viewpoint that SMAD4 hypermethylation is not a   common event in malignant tumors. Nevertheless, promoter hypermethylation   remains a candidate mechanism for SMAD4 inactivation in malignant tissue as a   potential cause of decreased or lost SMAD4 expression in certain tumor types,   and should be further investigated in different tumor types and larger   cohorts of patients.

Analysis of smad4 gene promoter methylation in pancreatic and endometrial cancers